peptide t peptide t peptide t is an hiv entry inhibitor discovered in 1986 by candace pert and michael ruff, a us neuroscientist and immunologist. peptide t, and its modified analog dala1-peptide t-amide (dapta), a drug in clinical trials, is a short peptide derived from the hiv envelope protein gp120 which blocks binding and infection of viral strains which use the ccr5 receptor to infect cells. peptide t names iupac name l-alanyl-l-seryl-l-threonyl-l-threonyl-l-threonyl-l-asparaginyl-l-tyrosyl-l-threonine identifiers cas number 106362-32-7 y 3d model (jsmol) interactive image chemspider 66081 pubchem cid 73352 unii 05dym3zs1x y inchi inchi=1s/c35h55n9o16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50h,10-12,36h2,1-5h3,(h2,37,51)(h,38,53)(h,39,56)(h,40,52)(h,41,55)(h,42,58)(h,43,57)(h,44,54)(h,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1key: iwhcajppwomxnw-lykmmfcusa-ninchi=1/c35h55n9o16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50h,10-12,36h2,1-5h3,(h2,37,51)(h,38,53)(h,39,56)(h,40,52)(h,41,55)(h,42,58)(h,43,57)(h,44,54)(h,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1key: iwhcajppwomxnw-lykmmfcubm smiles o=c(n(c(=o)n(c(=o)n(c(=o)n(c(=o)n(c(=o)n(c(=o)n(c(=o)o)(o)c)cc1ccc(o)cc1)cc(=o)n)(o)c)(o)c)(o)c)co)(n)c properties chemical formula c35h55n9o16 molar mass 857.872 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references peptide t has several positive effects related to hiv disease and neuro-aids. a fdg-pet neuro-imaging study in an individual with aids dementia who completed a 12-wk treatment with intranasal dapta, showed remission in 34 out of 35 brain regions after treatment. a placebo-controlled, three site, 200+ patient nih-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995. the results showed that dapta was not significantly different from placebo on the study primary end points. however, 2 of 7 domains, abstract thinking and speed of information processing, did show improvement in the dapta group (p<.05). furthermore, twice as many dapta-treated patients improved, whereas twice as many placebo patients deteriorated (p=.02). a sub-group analysis showed that dapta had a treatment effect and improved global cognitive performance (p=.02) in the patients who had more severe cognitive impairment. an analysis of antiviral effects from the 1996 nih study showed peripheral viral load (combined plasma and serum) was significantly reduced in the dapta-treated group. an eleven-person study for peptide t effects on cellular viral load showed reductions in the persistently infected monocyte reservoir to undetectable levels in most of the patients. elimination of viral reservoirs, such as the persistently infected monocytes or brain microglia, is an important treatment goal. peptide t clinical development was stopped due to the propensity of the liquid nasal spray to lose potency upon storage and shifted to its shorter oral analog, the pentapeptide ccr2/ccr5 antagonist rap-103 (receptor active peptide) for neuropathic pain and neurodegeneration. rap-103 also blocks ccr8, which may be important in neuropathic pain. inhibitors of ccr5, including dapta, prevent and reverse neurodegeneration and are therapeutic targets in stroke/brain injury and dementia, such as in parkinsons disease. popular culture in the 2013 biographical film dallas buyers club, protagonist ron woodroof (matthew mcconaughey) promotes the use of injected peptide t as a treatment for hiv/aids and alzheimer's disease and sues the fda over their efforts to limit his ability to use peptide t, as it was an unapproved medicine. additional information on woodroof's court challenge to the fda related to his obtaining access to peptide t can be found in the article by marsha cohen in hastings constitutional law quarterly (vol.18:471) . woodroof's challenge was in part responsible for the 1987 revisions to the fda investigational drug regulations that expanded access to experimental drugs for patients with serious diseases with no alternative therapies.